Luminal A-like, luminal B-like (HER2-), luminal B-like (HER2+), HER2+, and triple negative breast cancers were present in 117 (30.2%), 135 (34.9%), 50 (12.9%), 47 (12.1%), and 38 (9.9%) patients, respectively. Here, ERBB2 is linked to triple-negative breast carcinoma.